VMT-𝛼-GEN: Elegantly Designed Pb-212 Isotope Generator
Enables a nimble supply of therapeutic radioisotope with the power of alpha-particle therapy for cancer
We have developed a proprietary isotope generator, VMT-𝛼-GEN, to deliver our therapeutic isotope Pb-212 for supply to patients. With a half-life of 10.6 hours, Pb-212 is ideally suited to deliver powerful alpha-particle therapy to cancerous tumors, while representing a lower risk for off-target unintended effects and the potential for treatment on an outpatient basis.
- Abundant feedstock from nuclear and mining waste material
- On demand daily doses
- Auto-regenerates overnight
- ≃1 week shelf life
- Small footprint allows for benchtop use and simple logistics – the size of a coffee thermos
- Long-term supply contract with the National Isotope Development Center of the U.S. Department of Energy Isotope Program
Radionuclide generators such as VMT-𝛼-GEN are used commonly in radiopharmacies and nuclear medicine facilities across the world. The devices share a common characteristic of enabling the on-site production of a purified chemical form of the radionuclide that can be combined with targeting peptides that seek out cancerous tumors. Because the shelf life of VMT-𝛼-GEN is based on a longer-lived radionuclide (Ra-224), a single shipment of VMT-𝛼-GEN can be used to produce radiopharmaceutical doses daily, for up to a week or more. The device can then be returned to the manufacturer in approved packaging to eliminate radioactive waste from the medical center or radiopharmacy.